Our observations further demonstrate the importance of either screening for nonexon 12 NPM1 mutations with IHC, or whole NPM1 gene sequencing to identify rare NPM1 mutations outside of exon 12 for better classification of AML patients. This evidence concerns the gene NPM1 and acute myeloid leukemia.